Skip to main content
AAN.com
Views & Reviews
November 1, 1994

Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy)

November 1994 issue
44 (11) 2015

Abstract

We present the preliminary neuropathologic criteria for progressive supranuclear palsy (PSP) as proposed at a workshop held at the National Institutes of Health, Bethesda, MD, April 24 and 25, 1993. The criteria distinguish typical, atypical, and combined PSP. A semiquantitative distribution of neurofibrillary tangles is the basis for the diagnosis of PSP. A high density of neurofibrillary tangles and neuropil threads in the basal ganglia and brainstem is crucial for the diagnosis of typical PSP. Tau-positive astrocytes or their processes in areas of involvement help to confirm the diagnosis. Atypical cases of PSP are variants in which the severity or distribution of abnormalities deviates from the typical pattern. Criteria excluding the diagnosis of typical and atypical PSP are large or numerous infarcts, marked diffuse or focal atrophy, Lewy bodies, changes diagnostic of Alzheimer's disease, oligodendroglial argyrophilic inclusions, Pick bodies, diffuse spongiosis, and prion protein-positive amyloid plaques. The diagnosis of combined PSP is proposed when other neurologic disorders exist concomitantly with PSP.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 44Number 11November 1994
Pages: 2015

Publication History

Published online: November 1, 1994
Published in print: November 1994

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

J.-J. Hauw, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
S. E. Daniel, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
D. Dickson, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
D. S. Horoupian, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
K. Jellinger, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
P. L. Lantos, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
A. McKee, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
M. Tabaton, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
I. Litvan, MD
Raymond Escourolle Neuropathology Laboratory (Dr. Hauw), INSERM U 360, Hôpital de la Salpêtrière, Paris, France; the Parkinson's Disease Society Brain Tissue Bank and Department of Neuropathology (Dr. Daniel), Institute of Neurology, London, UK; the Department of Neuropathology (Dr. Dickson), Albert Einstein College of Medicine, Bronx, NY; the Department of Pathology (Neuropathology) (Dr. Horoupian), Stanford School of Medicine, San Francisco, CA; the Ludwig Boltzmann Institute of Clinical Neurobiology (Dr. Jellinger), Vienna, Austria; the Department of Neuropathology (Dr. Lantos), Institute of Psychiatry, London, UK; the Department of Neuropathology (Dr. McKee), Massachusetts General Hospital, Boston, MA; the Division of Neuropathology (Dr. Tabaton), Case Western Reserve University, Cleveland, OH; and the Neuroepidemiology Branch (Dr. Litvan), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Difficulties in diagnosing progressive supranuclear palsy, Russian neurological journal, 28, 2, (66-72), (2023).https://doi.org/10.30629/2658-7947-2023-28-2-66-72
    Crossref
  2. Brain aconitase activity is not decreased in progressive supranuclear palsy, Neurology, 59, 1, (137-138), (2023)./doi/10.1212/WNL.59.1.137
    Abstract
  3. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease, Neurology, 57, 8, (1497-1499), (2023)./doi/10.1212/WNL.57.8.1497
    Abstract
  4. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese , Neurology, 55, 6, (800-805), (2023)./doi/10.1212/WNL.55.6.800
    Abstract
  5. The tau gene A0 allele and progressive supranuclear palsy, Neurology, 53, 6, (1219-1219), (2023)./doi/10.1212/WNL.53.6.1219
    Abstract
  6. Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome, Neurology, 101, 3, (e289-e299), (2023)./doi/10.1212/WNL.0000000000207397
    Abstract
  7. Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension, Neurology, 93, 14, (e1339-e1347), (2023)./doi/10.1212/WNL.0000000000008197
    Abstract
  8. Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration, Neurology, 92, 21, (e2472-e2482), (2023)./doi/10.1212/WNL.0000000000007530
    Abstract
  9. [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy, Neurology, 90, 22, (e1989-e1996), (2023)./doi/10.1212/WNL.0000000000005610
    Abstract
  10. Frontal presentation in progressive supranuclear palsy, Neurology, 69, 8, (723-729), (2023)./doi/10.1212/01.wnl.0000267643.24870.26
    Abstract
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share